John Wang, MD

John Wang, MD, MSc, FACC, FSCAI, is Chief of the Cardiac Catheterization Laboratory at MedStar Union Memorial Hospital in Baltimore, MD. He specializes in complex angioplasty, chronic total occlusions, and trans-radial cardiac catheterizations. Dr. Wang is board-certified in Interventional Cardiology, Cardiovascular Disease, and Internal Medicine.

Widely published in his field, Dr. Wang has been principal investigator or sub-investigator on more than 20 studies. Presently, he is the national principal investigator of the OMEGA trial studying the latest generation of bare metal stents. Dr. Wang's research focuses on the safety and efficacy of new devices and technologies in interventional cardiology, especially research involving coronary stents. Dr. Wang conducts investigations into future generations of drug-eluting stents, including the SPIRIT IV, RESOLUTE, and PLATINUM trials, some of the largest randomized clinical trials comparing drug eluting stents. He also is leading the EXCEL study, a comparison of stenting to coronary artery bypass surgery in patients with left main stenoses and multi-vessel coronary artery disease.

Other areas of Dr. Wang's research interest include bifurcation stents (i.e., stents designed to treat branch-point disease) and bio-absorbable polymers and stents that are absorbed by the body over a period of months to years.

Dr. Wang received his undergraduate and medical degrees from the University of Chicago. He completed his internship, residency, and fellowship at the Brigham and Women's Hospital, Boston, MA. In addition, Dr. Wang received his Master of Science in Epidemiology from the Harvard School of Public Health.

Research Interests

Dr. John Wang's research interests include

Interventional cardiologySafety and efficacy of new devices and technologies in interventional cardiologyCoronary stents

Selected Publications

Recent examples of Dr. Wang's published research include

Hiroki I, Hermiller JB, Sood PR, Wang, JC, Cannon L, Maddux JE, Sudhir K, Stone GW. Performance of Everolimus-Eluting vs. Paclitaxil-Eluting Coronary Stents in Small Vessels: Results from the SPIRIT III and SPIRIT IV Clinical Trials. J of Interventional Cardiology. (In press). 2011.

Kereiakes DJ, Cutlip DE, Appelgate RJ, Wang JC, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRI IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). European Society of Cardiology - ESC Congress. J Am Coll Cardiol. 2010;56:2084-2089.

Kereiakes DJ, Cannon LA, Feldman RL, Popma JJ, Magorien R, Whitbourn R, Dauber IM, Rabinowitz AC, Ball MW, Bertolet B, Kabour A, Foster MC, Wang JC, Underwood P, Dawkins KD. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol 2010;56:264-271.

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. New England Journal of Medicine. 2010;362:1663-1674.